Aptose Biosciences Inc. (APTO) Expected to Post Earnings of -$0.16 Per Share

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to report ($0.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aptose Biosciences’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.18). Aptose Biosciences posted earnings of ($0.12) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 33.3%. The company is scheduled to issue its next quarterly earnings results on Tuesday, March 26th.

On average, analysts expect that Aptose Biosciences will report full-year earnings of ($0.86) per share for the current financial year, with EPS estimates ranging from ($0.88) to ($0.83). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.70) per share, with EPS estimates ranging from ($0.76) to ($0.59). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Aptose Biosciences.

Several analysts have recently issued reports on the company. Zacks Investment Research cut Aptose Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. HC Wainwright set a $9.00 price objective on Aptose Biosciences and gave the stock a “buy” rating in a report on Monday, December 3rd. Oppenheimer assumed coverage on Aptose Biosciences in a report on Thursday, January 24th. They set an “outperform” rating and a $6.00 price objective on the stock. Roth Capital reaffirmed a “buy” rating on shares of Aptose Biosciences in a report on Wednesday, December 12th. Finally, B. Riley assumed coverage on Aptose Biosciences in a report on Friday, November 16th. They set a “buy” rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Aptose Biosciences has an average rating of “Buy” and a consensus target price of $5.75.

Institutional investors and hedge funds have recently modified their holdings of the company. Noven Financial Group Inc. purchased a new stake in Aptose Biosciences during the 4th quarter valued at $27,000. Patriot Financial Group Insurance Agency LLC raised its holdings in Aptose Biosciences by 11.4% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 5,890 shares during the period. Citadel Advisors LLC purchased a new stake in Aptose Biosciences during the 3rd quarter valued at $125,000. Finally, Renaissance Technologies LLC raised its holdings in Aptose Biosciences by 1,130.9% during the 3rd quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock valued at $477,000 after buying an additional 168,501 shares during the period. 3.30% of the stock is currently owned by institutional investors and hedge funds.

Shares of APTO traded up $0.02 during mid-day trading on Monday, hitting $1.93. 1,661 shares of the stock were exchanged, compared to its average volume of 181,347. The stock has a market capitalization of $72.54 million, a price-to-earnings ratio of -3.71 and a beta of 1.81. Aptose Biosciences has a 52-week low of $1.78 and a 52-week high of $4.55.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Recommended Story: What is the return on assets formula?

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply